Fader, Amanda N <br/><br/>
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  07 2018 
 - 2044-2051 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2017.76.5966  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carboplatin--administration & dosage<br/>Cystadenocarcinoma, Serous--drug therapy<br/>Female<br/>Humans<br/>Middle Aged<br/>Neoplasm Staging<br/>Paclitaxel--administration & dosage<br/>Progression-Free Survival<br/>Receptor, ErbB-2--biosynthesis<br/>Trastuzumab--administration & dosage<br/>Uterine Neoplasms--drug therapy